Celebrity Media New York United Alliance Club Special Report: On September 14, 2026, the C³ Davos of Healthcare New York Healthcare Summit was held at The Union League Club in Manhattan. AmplifiDx, a medical diagnostics technology company, showcased a compact molecular point-of-care testing platform designed for clinical use. The device is compact and works with disposable testing cartridges, enabling physicians to test patient samples directly in their clinics and obtain results in approximately 15 minutes.
During an interview with Celebrity Media, an AmplifiDx representative explained that the platform uses molecular diagnostic technology and could be applied to respiratory infections, sexually transmitted infections, and other conditions. After collecting a patient sample, a healthcare professional places it into a dedicated testing cartridge, inserts the cartridge into the instrument, enters the required basic information, and starts the automated testing process.
For respiratory infections, the platform is being developed to test a single sample simultaneously for COVID-19, respiratory syncytial virus (RSV), influenza A, and influenza B. According to the company, the process is expected to take approximately 15 minutes from the time the sample is inserted into the instrument until the results become available.
Initial Commercial Focus on Sexually Transmitted Infections
Nancy Schoenbrunner, co-founder and CEO of AmplifiDx, said the company plans to launch a sexually transmitted infection testing panel as its first commercial product. Female patients would be able to provide vaginal swab samples, while male patients could provide urine samples.
According to the company, the test is being designed to identify chlamydia, gonorrhea, and trichomoniasis simultaneously. It would also detect a ciprofloxacin-resistance marker relevant to the treatment of gonorrhea. In addition to determining whether a patient has an infection, the test could provide information about antibiotic susceptibility, helping physicians assess whether ciprofloxacin may be appropriate or whether another treatment should be considered.
Schoenbrunner noted that providing antimicrobial-resistance information at the time an infection is diagnosed could help physicians select medications more precisely, avoid ineffective treatments, and reduce the risk of further contributing to antibiotic resistance.
A company representative said that when a patient is eligible for treatment with a lower-cost oral medication, it may be possible to avoid more expensive injectable treatment, potentially benefiting patients, physicians, and insurance payers. However, specific treatment decisions must still be made by physicians based on validated test results and applicable clinical guidelines.
Designed for Clinics, Emergency Departments, and Urgent Care Centers
AmplifiDx plans to deploy the system in primary care practices, sexually transmitted infection clinics, urgent care centers, and hospital emergency departments. Because the instrument is compact and requires relatively few operating steps, it could eventually enable healthcare facilities without large laboratory systems to perform molecular testing, provided that the necessary regulatory authorizations are obtained.
The company said its development team has interviewed and surveyed 323 physicians and clinical laboratory professionals to better understand acceptable instrument pricing, per-test cartridge costs, and practical workflow requirements. The company believes this market research will help determine the product’s future pricing strategy and clinical-use model.
The central value of a compact molecular point-of-care testing device is its potential to turn a process that traditionally requires sending samples to a laboratory and waiting hours or even days into one that can be completed during a single patient visit. If patients can receive their results before leaving the clinic, physicians may be able to make treatment decisions more quickly while reducing the likelihood of repeat visits or patients being lost to follow-up.
Product Remains in the Development and Regulatory Preparation Stage
Although the platform shows potential for use in community-based healthcare settings, the AmplifiDx website currently states that its related diagnostic products have not been approved or cleared by the U.S. Food and Drug Administration (FDA).
Whether the product can eventually be used widely in general clinical settings may depend not only on obtaining the appropriate FDA authorization but also on securing a CLIA waiver, demonstrating adequate testing accuracy, establishing an acceptable per-test cost, obtaining insurance reimbursement, ensuring a reliable cartridge supply, and integrating the system effectively into clinical workflows.
Accordingly, this compact testing platform should currently be regarded as a medical product under development and in preparation for commercialization—not as an approved device available for routine clinical diagnosis. If it successfully completes clinical validation and obtains the required regulatory authorizations, it could provide clinics with a faster and more convenient option for infection testing and help advance a model of on-site testing, immediate diagnosis, and timely treatment.
